Insurers cut back GLP-1 coverage as demand soars: Found study

As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

Ozempic: How the Diabetes Drug Works and Why It's Such a Big Deal for Weight Loss - WSJ

GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type

IPN 2023 January by IPN Communications LTD - Issuu

Ozempic: Insurance Providers Are Ending Coverage of Weight Loss Drugs

GLP-1 Coverage in Employer Plans Could Nearly Double in 2024

Weight loss drug Wegovy reduces heart disease risk

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

GLP1-RAs linked with reduced risk of depression, study claims

GLP-1 WEIGHT LOSS INJECTION FOR MEN: BREAKING BARRIORS

2024 Spring Magellan Rx Report by Magellan Rx Management - Issuu

IPN 2023 January by IPN Communications LTD - Issuu

Ozempic in Canada: Diabetes drug being used for weight loss